Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1644 1653
This examiner grants 64% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18020611 | TARGETED PROTEIN DEGRADATION IN THERAPEUTIC CELLS | Non-Final OA | The Regents of the University of California |
| 16185369 | METHODS OF DECREASING TRISULFIDE BONDS DURING RECOMBINANT PRODUCTION OF POLYPEPTIDES | Final Rejection | GENENTECH, INC. |
| 18015709 | THERAPEUTIC HYDROGEL FOR THE DELIVERY OF CAR-T CELLS | Non-Final OA | NORTH CAROLINA STATE UNIVERSITY |
| 18437185 | GENERATING CIK NKT CELLS FROM CORD BLOOD | Final Rejection | ImmunityBio, Inc. |
| 17995985 | ENGINEERED INTERLEUKIN-22 POLYPEPTIDES AND USES THEREOF | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17995986 | ENGINEERED IL-12 AND IL-23 POLYPEPTIDES AND USES THEREOF | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17793024 | PERICYTE-SPARING THERAPY | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17765043 | ELUTION OF MONOCLONAL ANTIBODIES IN PROTEIN A AFFINITY CHROMATOGRAPHY | Final Rejection | Merck Patent GmbH |
| 17998388 | FORMULATIONS OF ANTI-IL-33 ANTIBODIES | Final Rejection | MedImmune Limited |
| 18963973 | TEMPERATURE-RESPONSIVE VIRUS STORAGE SYSTEM | Final Rejection | Trizell Ltd. |
| 18538052 | TEMPERATURE-RESPONSIVE VIRUS STORAGE SYSTEM | Final Rejection | Trizell Ltd. |
| 17923029 | METHODS FOR TREATING OR REDUCING THE SEVERITY OF A VIRAL INFECTION | Non-Final OA | Washington University |
| 17904706 | Bispecific GD2 and B7H3 Binding Molecules and Methods of Use | Non-Final OA | WISCONSIN ALUMNI RESEARCH FOUNDATION |
| 16547907 | EXPANSION OF HPSC-DERIVED GRANULOCYTIC AND LYMPHOID PROGENITORS WITH UM171 | Final Rejection | Wisconsin Alumni Research Foundation |
| 18478247 | ANTI-CD83 CHIMERIC ANTIGEN RECEPTOR EXPRESSING T REGULATORY CELLS | Final Rejection | H. Lee Moffitt Cancer Center and Research Institute, Inc. |
| 18421826 | METHODS FOR MANUFACTURING T CELLS EXPRESSING OF CHIMERIC ANTIGEN RECEPTORS AND OTHER RECEPTORS | Final Rejection | City of Hope |
| 18277367 | TRUNCATED DOMAIN IV EGFR AND USES THEREOF | Non-Final OA | CITY OF HOPE |
| 17789930 | METHODS OF MAKING AND USING REGULATORY T CELLS AND EFFECTOR T CELLS HAVING CHIMERIC ANTIGEN RECEPTORS TARGETED TO CD6, CD19, AND/OR AN IL-13R FOR TREATMENT OF AUTOIMMUNE DISORDERS AND CANCERS | Non-Final OA | CITY OF HOPE |
| 17922484 | NEGATIVELY CHARGED PARTICLES FOR THE TREATMENT OF CYTOKINE STORM SYNDROME (CSS) AND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) | Final Rejection | onCOUR Pharma, Inc. |
| 17924013 | Neoantigenic Epitopes Associated with SF3B1 Mutations | Non-Final OA | Institut National de la Santé et de la Recherche Médicale |
| 18010783 | ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCER | Non-Final OA | Genmab A/S |
| 17788730 | NOVEL ANTI-FGFR2B ANTIBODIES | Final Rejection | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. |
| 18278956 | ANTIBODIES THAT BIND CD123 AND GAMMA-DELTA T CELL RECEPTORS | Non-Final OA | LAVA THERAPEUTICS N.V. |
| 18082841 | CHIMERIC ANTIGEN RECEPTOR REGENERATIVE GAMMA DELTA T CELLS | Final Rejection | CREATIVE MEDICAL TECHNOLOGIES, INC. |
| 17926454 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NECTIN-4 AND USES THEREOF | Final Rejection | BicycleTx Limited |
| 18030225 | METHODS FOR TREATING CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | Non-Final OA | SEAGEN INC. |
| 17618076 | Soluble Complement Receptor Type 1 Variant Conjugates and Uses Thereof | Final Rejection | CSL Innovation Pty., Ltd. |
| 18174565 | COMPOSITIONS AND METHODS OF CELLULAR IMMUNOTHERAPY | Non-Final OA | CRAGE medical Co., Limited |
| 18250422 | METHODS OF INDUCING ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY (ADCC) USING MODIFIED NATURAL KILLER (NK) CELLS | Non-Final OA | Shoreline Biosciences, Inc. |
| 17028300 | TREATMENT METHODS UTILIZING STEM CELL MOBILIZERS AND IMMUNOSUPPRESSIVE AGENTS | Final Rejection | MedRegen, LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy